SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Repros Therapeutics Inc. to Allergan plc is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Repros Therapeutics Inc. (“Repros Therapeutics” or the “Company”) (NASDAQ:RPRX) stock prior to December 12, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Repros Therapeutics to Allergan plc for $0.67 per share. To learn more about the action and your rights, go to:

http://www.zlk.com/mna/repros-therapeutics-inc

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The investigation concerns whether the Board of Repros Therapeutics breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Allergan plc is underpaying for Repros Therapeutics shares, thus unlawfully harming Repros Therapeutics shareholders.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171212005964/en/